Advances in studies of tyrosine kinase inhibitors and their acquired resistance.

about

Comparative Methylome Analysis Reveals Perturbation of Host Epigenome in Chestnut Blight Fungus by a Hypovirus.

P2860

Q55294535-E555821F-4D35-4322-9799-C101EE1B8B54

P2860

Advances in studies of tyrosine kinase inhibitors and their acquired resistance.

Item

http://www.wikidata.org/entity/Q49887903

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Advances in studies of tyrosine kinase inhibitors and their acquired resistance.

@en

Advances in studies of tyrosine kinase inhibitors and their acquired resistance.

@nl

type

Item

label

Advances in studies of tyrosine kinase inhibitors and their acquired resistance.

@en

Advances in studies of tyrosine kinase inhibitors and their acquired resistance.

@nl

prefLabel

Advances in studies of tyrosine kinase inhibitors and their acquired resistance.

@en

Advances in studies of tyrosine kinase inhibitors and their acquired resistance.

@nl

P1476

Advances in studies of tyrosine kinase inhibitors and their acquired resistance.

@en

P2093

Lei Bi

http://www.w3.org/2001/XMLSchema#string

Qin Wang

http://www.w3.org/2001/XMLSchema#string

Qinlian Jiao

http://www.w3.org/2001/XMLSchema#string

Shuliang Song

http://www.w3.org/2001/XMLSchema#string

Yidan Ren

http://www.w3.org/2001/XMLSchema#string

Yun-Shan Wang

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer

New therapeutic strategies for BRAF mutant colorectal cancers

ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance

Targeting RTK Signaling Pathways in Cancer

Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors

Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase Domain

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.

P2888

s12943-018-0801-5

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1186/S12943-018-0801-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2018-02-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1101066802

http://www.w3.org/2001/XMLSchema#string

P698

29455664

http://www.w3.org/2001/XMLSchema#string

P921

Aillse

mechanism of action

P932

5817861

http://www.w3.org/2001/XMLSchema#string

Advances in studies of tyrosine kinase inhibitors and their acquired resistance.

about

P2860

P2860

Advances in studies of tyrosine kinase inhibitors and their acquired resistance.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P2888

P304

P31

P356

P433

P478

P5008

P577

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P2888

P304

P31

P356

P433

P478

P5008

P577

P6179

P698

P921

P932